EAY 131 NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (MATCH)


This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

Treatment Arms:

Based on genetic abnormalities; such as mutations, amplifications, or translocations. Courses repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.


After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 1 year.

Partial Eligibility Criteria:

  • Patients must have a diagnosis of cancer and have progressed following at least one line of standard systemic therapy and no other standard treatment exists that has been shown to prolong overall survival
  • Patients must have tumor amenable to image guided or direct vision biopsy and be willing and able to undergo a tumor biopsy or have had tissue collected within 6 months.
  • Patients with uncontrolled illness including, but not limited to, ongoing or active infection, cardiac, central nervous system, or autoimmune diseases
  • Patients must be able to swallow tablets or capsules.

For additional information, please contact the Research Nurses:

  • Nona Blauvelt, RN, MSN, AOCN; 610-738-2522
  • Susan Metzger, RN, MSN; 610-738-2515
Share This Page: